Hydantoin derivative compounds, methods of use and methods of treatment

Patent metadata

Field	Value
Publication number	US-10793526-B2
Application number	US-201916540556-A
Country	US
Kind code	B2
Filing date	Aug 14, 2019
Priority date	Nov 28, 2016
Publication date	Oct 6, 2020
Grant date	Oct 6, 2020

Abstract

The present disclosure provides compositions including a hydantoin derivative compound, pharmaceutical compositions including a hydantoin derivative compound, methods of treatment of a condition (e.g., bacterial infection) or disease, methods of treatment using compositions or pharmaceutical compositions, and the like.

First claim

We claim at least the following:

1. A method of treating a bacterial infection comprising:
delivering, to a subject having a bacterial infection, a composition comprising a therapeutically effective amount of a hydantoin derivative compound, or a pharmaceutically acceptable salt of the hydantoin derivative compound, to treat the bacterial infection, wherein the hydantoin derivative compound has the following structure:

wherein D 1 is a hydantoin core, D 2 is a membrane interacting domain, R 1 is a hydrophobic group, R 2 is selected from the group consisting of a NH 2 group, an aminobutyl group, an aminopentyl group, an aminohexyl group, and an aminopropyl group, and X is a lipid tail.

2. The method of claim 1 , wherein the infection is caused by one or more bacteria selected from the group consisting of: methicillin-resistant Staphylococcus aureus , methicillin-resistant Staphylococcus epidermidis , Vancomycin-Resistant Enterococci, Escherichia coli, Klebsiella pneumoniae , and Pseudomonas aeruginosa.

3. The method of claim 1 , wherein the lipid tail X is a 5 to 15 carbon alkyl group.

4. The method of claim 3 , wherein the lipid tail X is selected from a 10 to 12 carbon linear alkyl group.

5. The method of claim 3 , wherein R 1 is an ethyl group, a phenyl group, meta-chlorobenzyl, indole, biphenyl, terphenyl, or 6-chloro indole.

6. The method of claim 1 , wherein the hydantoin derivative compound has the following structure:

7. The method of claim 1 , wherein R 1 is an alkyl group, aryl group, or a cycloalkyl group, each of which is substituted or unsubstituted.

8. The method of claim 7 , wherein the lipid tail X is a 5 to 15 carbon alkyl group.

9. The method of claim 8 , wherein the lipid tail X is selected from a 10 to 12 carbon linear alkyl group.

10. The method of claim 1 , wherein R 1 is an ethyl group, a phenyl group, meta-chlorobenzyl, indole, biphenyl, terphenyl, or 6-chloro indole.

11. The method of claim 2 , wherein the bacterial infection is caused by gram positive bacteria.

12. The method of claim 2 , wherein the bacterial infection is caused by gram negative bacteria.

Assignees

• Cai Jianfeng
• Su Ma
• Nimmagadda Alekhya
• Teng Peng
• Univ South Florida

Inventors

• Cai Jianfeng
• Su Ma
• Nimmagadda Alekhya
• Teng Peng

Classifications

• C07D233/76

  with substituted hydrocarbon radicals attached to the third ring carbon atom · CPC title

• A61K31/4166

  having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin · CPC title

• C07D233/72 Primary

  Two oxygen atoms, e.g. hydantoin · CPC title